Trevor Martin, Mammoth Biosciences CEO (Ore Huiying/Bloomberg via Getty Images)
April 25, 2024 07:00 AM EDT
Deals

Re­gen­eron and Mam­moth strike $100M deal to pair tiny CRISPR ed­i­tors with new de­liv­ery idea

Andrew Dunn

Senior Biopharma Correspondent

Re­gen­eron is ex­pand­ing its ge­net­ic med­i­cine ef­forts and will work with Cal­i­for­nia start­up Mam­moth Bio­sciences on gene-edit­ing pro­grams reach­ing parts of the hu­man body be­yond …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

A service from the Financial Times